Sarah Patel's Avatar
published in Blogs
Nov 28, 2022
Biogen (BIIB, $291.61) shares slump, amidst reports of patient death in Eisai Alzheimer's death

Biogen (BIIB, $291.61) shares slump, amidst reports of patient death in Eisai Alzheimer's death

Biogen  shares plunged on Monday, following reports that a woman who participated in a trial of the drugmaker's developing Alzheimer's treatment died due to a brain hemorrhage. The company is developing the drug with  Eisai Co.

According to Science.org, the case involved a 65-year-old woman who died of a massive brain hemorrhage following a stroke and a type of brain swelling and bleeding in a trial of Eisai. The report mentioned that the bleeding started after the patient received an anti-clotting drug.

Biogen and Eisai have published very limited data from the trial. More results are expected to be presented at a conference this week.

Related Tickers: BIIB